Colorectal cancer (CRC) is a major public health concern as it is among the third most common cancer in China after lung cancer. The China Colorectal Cancer market is witnessing high growth on account of the increasing prevalence of cancer cases, surging awareness among people along with rising in ageing population, and paradigm shift of individual toward sedentary lifestyle. In 2018, 12.8% of colorectal cases were diagnosed in Chinese male. However, an increasing number of a new product launch by the market players, and growing awareness about the benefits of generic drugs are projected to fuel the growth of the market in the forthcoming timeline.
According to MarkNtel Advisors’ research report “China Colorectal Cancer Market Analysis, 2021”, the China Colorectal Cancer market is anticipated to grow at a CAGR of around 3% during 2021-26F. The increasing R&D by the pharma companies for new drug development, surging government initiative by launching a various awareness campaign on colorectal cancer along with escalating late-stage pipeline therapies and significant growth in the number of colorectal cancer screening programs for early cancer detection are strongly contributing toward the growth of the market over the forecast period.
“China Colorectal Cancer Market Analysis, 2021” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for Colorectal Cancer providers across the Globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.
North-West Region Acquired Significant Market Share
Based on Region, North-West region acquired a significant market share in the China Colorectal Cancer market in 2019. The escalation government initiative to conduct mass CRC screening Programme at Guangzhou as it is the third-largest city in mainland China. Along with, burgeoning incidences of colorectal cancer and funding raising by creative biosciences, a Guangzhou cancer screening and cancer diagnostic kit maker for early colorectal cancer test kit are expected to bolster the growth of the Colorectal Cancer Market in the forthcoming period as stated in MarkNtel Advisors’ research report “China Colorectal Cancer Market Analysis, 2021”.
According to MarkNtel Advisors’, the key players with a considerable market share in the China Colorectal Cancer market are Amgen China, Bristol-Myers Squibb, Bayer AG, Merck KGaA, Roche (China) Co., Ltd., Eli Lilly and Company, Sanofi China, Taiho Pharmaceutical, Novartis AG, Pfizer Inc. etc.
Key questions answered in the study: